CY1122385T1 - Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β - Google Patents

Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β

Info

Publication number
CY1122385T1
CY1122385T1 CY20191101067T CY191101067T CY1122385T1 CY 1122385 T1 CY1122385 T1 CY 1122385T1 CY 20191101067 T CY20191101067 T CY 20191101067T CY 191101067 T CY191101067 T CY 191101067T CY 1122385 T1 CY1122385 T1 CY 1122385T1
Authority
CY
Cyprus
Prior art keywords
tumor
selective
modified
adeno
mutants
Prior art date
Application number
CY20191101067T
Other languages
Greek (el)
English (en)
Inventor
Tony Reid
Farah Hedjran
Shantanu Kumar
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1122385T1 publication Critical patent/CY1122385T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CY20191101067T 2009-03-02 2019-10-10 Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β CY1122385T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15682209P 2009-03-02 2009-03-02
PCT/US2010/025926 WO2010101921A2 (en) 2009-03-02 2010-03-02 Tumor-selective e1a and e1b mutants
EP10749205.0A EP2403951B1 (en) 2009-03-02 2010-03-02 Tumor-selective adenovirus e1a and e1b mutants

Publications (1)

Publication Number Publication Date
CY1122385T1 true CY1122385T1 (el) 2021-01-27

Family

ID=42710189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101067T CY1122385T1 (el) 2009-03-02 2019-10-10 Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β

Country Status (15)

Country Link
US (6) US9073980B2 (OSRAM)
EP (4) EP3029144B1 (OSRAM)
JP (5) JP6072414B2 (OSRAM)
KR (4) KR102150027B1 (OSRAM)
CY (1) CY1122385T1 (OSRAM)
DK (2) DK3029144T3 (OSRAM)
ES (2) ES2750305T3 (OSRAM)
HR (2) HRP20151396T1 (OSRAM)
HU (2) HUE026386T2 (OSRAM)
LT (1) LT3029144T (OSRAM)
PL (2) PL2403951T3 (OSRAM)
PT (2) PT3029144T (OSRAM)
SI (2) SI2403951T1 (OSRAM)
SM (2) SMT201900565T1 (OSRAM)
WO (1) WO2010101921A2 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2403951T1 (sl) 2009-03-02 2016-04-29 The Regents Of The University Of California Tumorsko selektivni mutanti adenovirusa e1a in e1b
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN106062207B (zh) 2013-07-19 2020-07-03 路德维格癌症研究有限公司 全基因组且靶向的单体型重构
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
CA3038526A1 (en) * 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
KR20190128634A (ko) * 2017-01-30 2019-11-18 에피센트알엑스, 인코포레이티드 다중 트랜스진 재조합 아데노바이러스
CN110741081B (zh) 2017-01-30 2024-07-23 埃皮辛特瑞柯斯公司 肿瘤选择性tata盒和caat盒突变体
KR102643016B1 (ko) * 2017-04-10 2024-02-29 에피센트알엑스, 인코포레이티드 재조합 바이러스의 제조 방법
EA201990822A1 (ru) * 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
WO2018218083A1 (en) * 2017-05-24 2018-11-29 Epicentrx, Inc. Anti-angiogenic adenovirus
NZ759833A (en) * 2017-05-26 2023-01-27 Epicentrx Inc Recombinant adenoviruses carrying transgenes
CA3077223A1 (en) 2017-09-27 2019-04-04 Epicentrx, Inc. Immunomodulatory fusion proteins
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2019191494A1 (en) * 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
CN113015806A (zh) * 2018-08-31 2021-06-22 奥尔卡治疗有限公司 包含糖原合酶激酶-3(gsk3)编码区的重组的具有复制能力的病毒和杀伤异常细胞的方法
CN114761546A (zh) 2019-10-08 2022-07-15 波士顿学院董事会 含有多个不同非天然氨基酸的蛋白质以及制备和使用此类蛋白质的方法
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4114449A2 (en) 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN114262691A (zh) * 2020-09-16 2022-04-01 杭州康万达医药科技有限公司 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途
WO2024015876A1 (en) 2022-07-13 2024-01-18 Epicentrx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof
CN118931897A (zh) * 2024-06-27 2024-11-12 中山大学 一种识别肿瘤细胞并诱导其焦亡的基因、重组载体和重组病毒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
EP0716148B1 (en) * 1993-09-15 2004-01-02 Chiron Corporation Recombinant alphavirus vectors
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5902925A (en) 1996-07-01 1999-05-11 Integrated Sensor Solutions System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
DK1135514T3 (da) * 1999-01-28 2009-09-07 Onyx Pharma Inc E1b-deleteret adenovirale shuttle-vektorer
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
US7125705B2 (en) * 2000-04-28 2006-10-24 Genzyme Corporation Polynucleotides for use in recombinant adeno-associated virus virion production
WO2002018550A1 (en) * 2000-08-25 2002-03-07 The General Hospital Corporation Selective precipitation of viruses
CN1183250C (zh) 2000-12-01 2005-01-05 卫健生物科技有限公司 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
GB0117198D0 (en) 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
JP2005532829A (ja) * 2002-07-18 2005-11-04 インヴィトロジェン コーポレーション 組換え部位を含むウイルスベクター
WO2004020971A2 (en) * 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
CA2590257A1 (en) * 2003-11-14 2005-06-09 Per Sonne Holm Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2006070024A2 (de) * 2004-12-31 2006-07-06 Per Sonne Holm E1 -minus adenoviren und deren verwendung
KR101252065B1 (ko) * 2007-04-20 2013-04-12 다카라 바이오 가부시키가이샤 유전자 치료를 위한 벡터
SI2403951T1 (sl) 2009-03-02 2016-04-29 The Regents Of The University Of California Tumorsko selektivni mutanti adenovirusa e1a in e1b

Also Published As

Publication number Publication date
US20210171917A1 (en) 2021-06-10
SI2403951T1 (sl) 2016-04-29
US20190136204A1 (en) 2019-05-09
JP2016028035A (ja) 2016-02-25
EP4123030A1 (en) 2023-01-25
KR20110122866A (ko) 2011-11-11
EP3029144B1 (en) 2019-07-10
KR102020018B1 (ko) 2019-09-09
US11618888B2 (en) 2023-04-04
JP6375273B2 (ja) 2018-08-15
WO2010101921A3 (en) 2011-01-06
EP2403951A4 (en) 2012-08-22
JP2020078326A (ja) 2020-05-28
KR20190104643A (ko) 2019-09-10
SMT201500329B (it) 2016-02-25
US20230272349A1 (en) 2023-08-31
PL2403951T3 (pl) 2016-04-29
PT3029144T (pt) 2019-10-28
DK2403951T3 (en) 2016-01-11
KR20170077278A (ko) 2017-07-05
EP3591059B1 (en) 2022-07-20
HRP20151396T1 (hr) 2016-03-25
HUE046565T2 (hu) 2020-03-30
KR20180049188A (ko) 2018-05-10
JP2018113971A (ja) 2018-07-26
EP3591059A1 (en) 2020-01-08
KR101752910B1 (ko) 2017-06-30
ES2750305T3 (es) 2020-03-25
JP2012519014A (ja) 2012-08-23
PT2403951E (pt) 2016-01-29
ES2557812T3 (es) 2016-01-28
SI3029144T1 (sl) 2019-11-29
US20160017294A1 (en) 2016-01-21
JP6817979B2 (ja) 2021-01-20
EP3029144A1 (en) 2016-06-08
EP2403951A2 (en) 2012-01-11
US20250327037A1 (en) 2025-10-23
LT3029144T (lt) 2019-10-25
SMT201900565T1 (it) 2019-11-13
HUE026386T2 (en) 2016-06-28
HRP20191808T1 (hr) 2019-12-27
WO2010101921A2 (en) 2010-09-10
JP6072414B2 (ja) 2017-02-01
KR102150027B1 (ko) 2020-10-26
US20110318311A1 (en) 2011-12-29
JP2022023074A (ja) 2022-02-07
DK3029144T3 (da) 2019-10-21
US9073980B2 (en) 2015-07-07
JP7326396B2 (ja) 2023-08-15
US10876097B2 (en) 2020-12-29
KR101922539B1 (ko) 2018-11-27
US12195766B2 (en) 2025-01-14
PL3029144T3 (pl) 2020-06-01
EP2403951B1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
CY1122385T1 (el) Επιλεκτικα σε ογκο μεταλλαγματα αδενοϊου ε1α και ε1β
CY1125475T1 (el) Χρηση οξυγονωμενης θειικης χοληστερολης (ocs) για την αντιμετωπιση της νεφρικης δυσλειτουργιας
EP3890499A4 (en) Use of lactase to provide high gos fiber level and low lactose level
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
CL2016001507A1 (es) Compuestos para tratar pacientes con células cancerosas mutantes ros1
CY1120337T1 (el) Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης
BRPI0809663A2 (pt) Composição de vírus vivo atenuado, método de diminuição da inativação de composição de vírus vivo atenuado e kit respectivo
BR112019024813A2 (pt) adenovírus recombinantes portando transgenes
EP2139423A4 (en) SURGICAL PACKAGE AND BOWL
EP2558478A4 (en) AT 5 POSITIONS MODIFIED PYRIMIDINES AND THEIR USE
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
GB2475799A (en) Hypoxia inducing factor (hif) stabilising glasses
EP2118123A4 (en) STABILIZED P53 PEPTIDES AND ITS USES
CY1110002T1 (el) Τροποποιημενη πρωτεϊνη ηεχον αδενοϊου και χρησεις αυτης
MX354450B (es) Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
BR112015032690A8 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
MX388981B (es) Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
NZ600974A (en) Binding members for human cytomegalovirus
BR112012001043A2 (pt) tinturas fluorescentes e uso das mesmas
WO2017062511A8 (en) Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
EP2170373A4 (en) THERMOSTABILIZATION OF PROTEINS
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение